Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Investment friend checked into ONCY

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Feb 09, 2021 9:14pm

252 Views

Post# 32521046

RE:RE:RE:Investment friend checked into ONCY

We have one product but it has many many applications. We own the property rights to a mechanism to make your immune system much more active in both the primary and secondary responses, and then to invade cancer cells with a CI and kill them. It works on many cancer types, including metastatic disease.

Does that sound like it is worthwhile? Does that sound like it works in a "game-changing" way?

It does from my viewpoint, which is why I own it.

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”